Publication
The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Authors not recorded
Cancer Biomark2013PMID 24595080stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugCisplatincivic_curation1.00
- drugGemcitabinecivic_curation1.00
- geneRRM1civic_curation1.00
- variantRRM1 Underexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24595080
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RRM1 Underexpression1 | ||||||||
| Cisplatin + GemcitabineCombination | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID2905In the personalized therapy group of this study, patients received chemotherapy based on RRM-1 IHC expression levels, whereas the standard therapy group received non-customized chemotherapy. There wer… (full text at CIViC) PMID 24595080 · Nie et al., 2013 · Open in CIViC | civic |